



Comparative evaluation of chemical equivalence of some commercially available brands of Gatifloxacin tablet

Kapil Kalra^{1*}, Nazim Ali² and Himanshu Kumar³

1, Department of Pharmacy, Alpine College of Management & Technology, Dehradun, (U.K.) - India

2, Dev Bhoomi Institute of Pharmacy & Research, Dehradun, (U.K.) - India

3, Kanak Manjari Institute of Pharmaceutical Sciences, Rourkela, (Orissa) - India

Abstract

This study was undertaken with the objective of evaluating of six brands of Gatifloxacin tablets and the chemical equivalency with the use of an analytical method, which will be easy to use, accurate, reproducible, simple, and inexpensive. The chemical equivalence of six brands of Gatifloxacin tablets were assessed through the non-aqueous titration procedure with the use of crystal violet solution indicator. The non-aqueous titrimetric procedure showed that the excipients did not affect the procedure; with three brands having values within the range specified. While the remaining three brands gave lower values. The non-aqueous titrimetric procedure used in this study is simple, inexpensive, and easy to use and could be used in routine monitoring of the quality of Gatifloxacin tablets, especially in the absence of high technology equipments that are not easily available in most developing countries.

Key-Words: Gatifloxacin tablets, non-aqueous titration, chemical equivalence

Introduction

Gatifloxacin sold under the brand names Gatiflo, Tequin and Zymar, is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. Bristol-Myers Squibb introduced Gatifloxacin in 1999 under the proprietary name Tequin for the treatment of respiratory tract infections, having licensed the medication from Kyorin Pharmaceutical Company of Japan. Allergan produces an eye-drop formulation called Zymar. In many countries, gatifloxacin is also available as tablets and in various aqueous solutions for intravenous therapy. Gatifloxacin is currently available only in the US and Canada as an ophthalmic solution. In China it is sold in tablet as well as in eye drop formulations. Gatifloxacin was banned in India on the 18th of March along with Tegaserod. A statement from the health ministry said: 'The use of the following drugs is likely to involve certain risks to human beings, whereas safer alternatives to the said drugs are available.'

The move comes after international studies revealed that Gatifloxacin posed 17 times higher risk of developing serious hyperglycemia (high blood sugar) than other antibiotics in elderly patients. The introduction of generic drug product from multiple sources into the health care delivery system of many developing countries was aimed at improving the overall healthcare delivery systems in such countries. However, this has been accompanied by a variety of problems of which the most critical is the widespread distribution of fake and substandard drug products. The need to select one product from among several generic drug products of the same active ingredients during the course of therapy is a cause of concern to a healthcare practitioner. The first stage in ascertaining the therapeutic equivalence of any drug product involves ascertaining the chemical and biopharmaceutical equivalency of such drug product¹⁻⁴. The objective of this study was to evaluate the chemical equivalence of six brands nimusilide tablets of an analytical method, which will be easy to use, simple, and inexpensive with results, which compare favourably with established official methods.

Material and methods

Gatifloxacin pure powder was a gift from Windlass Pharmaceutical Industry, Dehradun while the various brands of the tablets were obtained from retail Pharmacies Dehradun. Reagents used include glacial

*** Corresponding Author:**

E-mail: kapil752003@yahoo.com

acetic acid, perchloric acid, acetic anhydride, potassium hydrogen phthalate, hydrochloric acid, crystal violet solution. Six different brands of Gatifloxacin tablets and the innovator brand with labeled contents of 100mg each.⁵⁻⁸

The percent of Gatifloxacin was determined by applying the following equations:-

$$M_1 V_1 = M_2 V_2$$

$$M_2 = \frac{M_1 V_1}{V_2}$$

Where, M_2 =Molarity of Gatifloxacin in sample solution, M_1 = Molarity of perchloric acid, V_1 =Volume of perchloric acid, V_2 =Volume of sample solution

$$\text{Strength of Gatifloxacin (gm/ml)} = \frac{\text{Mol. Wt of Ciprofloxacin HCl} \times M_2}{1000}$$


$$\text{Percentage of Gatifloxacin} = \frac{\text{wt of Gatifloxacin in sample solution}}{500} \times 100$$

Chemical content determination

Gatifloxacin pure powder: - 0.1g, 0.2g and 0.3g were dissolved in glacial acetic (15ml) acid, followed by the addition of freshly prepared mercuric (II) acetate solution (0.5ml, 1.0ml and 1.5ml respectively) and acetic anhydride (2ml,4ml and 5ml respectively). The solutions were titrated against 0.1M acetous perchloric acid using 0.5%w/v crystal violet solution as indicator until a bluish – green end point. Blank titrations were carried out using 15ml glacial acetic acid. Titre values were adjusted by deducting the blank determination from the assay. This was carried out in triplicate Gatifloxacin tablets (Innovator brand):- Amounts of the crushed tablet material equivalent to 0.1g, 0.2g, 0.3g of pure Gatifloxacin in the tablet dosage form of the innovator brand were weighed. These were dissolved in 15ml glacial acetic acid, followed by the addition of freshly prepared mercuric (II) acetate solution (0.5ml, 1.0ml and 1.5ml respectively) and acetic anhydride (2ml,4ml and 5ml respectively). The solution was titrated against 0.1M acetous perchloric acid using 0.5%w/v crystal violet solution as indicator until a bluish – green end point. Blank titrations were carried out using 15ml glacial acetic acid. Titre values were adjusted by deducting the blank determination from the assay. The procedure was carried out in triplicate. The procedure was then applied to ten other brands of Gatifloxacin tablets sourced from various pharmacy outlets.

Results and Conclusion

The result of the non-aqueous titration of Gatifloxacin pure powder at 0.1g, 0.2g and 0.3g and the equivalent weights of the powdered tablets of the innovator brand is presented in Table1. The values obtained with the different concentrations showed that the excipients did not affect the procedure. The chemical content determination procedure used in this study involves the modification of the non-aqueous titration specified in B.P for Gatifloxacin HCl pure powder. The modification involves the addition of acetic anhydride and mercuric (II) acetate solution, using 5%w/v crystal violet solution as indicator. The application of the non-aqueous titrimetric procedure was based on the following equation;



The Gatifloxacin pure powder at 0.1, 0.2 & 0.3g gave 99.12 ± 1.48 , 100.17 ± 1.54 &

100.37 ± 1.03 %w/w respectively which is in line with the USP 1990 specification of 90 –

110%w/w. Similarly, equivalent weights of the powdered Gatifloxacin tablets (innovator brand) gave 99.97 ± 2.78 , 98.01 ± 1.89 & 100.27 ± 2.05 %w/w respectively. The procedure was repeatable with consistent results and very good interday and intraday precision. The excipients of the tablets did not interfere with the assay procedure and result as the colour end point was clear and stable.

The non- aqueous titrimetric procedure for the assay of Gatifloxacin used in this study is simple, inexpensive, reproducible and easy to use and could be used in routine monitoring of the quality of Gatifloxacin pure powder and tablets, especially in the absence of high technology equipment that are not easily available in most developing countries.

References

- Burka JM, Bower KS, Vanroekel RC, Stutzman RD, Kuzmowych CP, Howard RS (July 2005). "The effect of fourth-generation fluoroquinolones gatifloxacin and moxifloxacin on epithelial healing following photorefractive keratectomy". *Am. J. Ophthalmol.* **140** (1): 83–7.
- Park-Wyllie, Laura Y.; David N. Juurlink, Alexander Kopp, Baiju R. Shah, Therese A. Stukel, Carmine Stumpo, Linda Dresser, Donald E. Low, Muhammad M. Mamdani (March 2006). "Outpatient Gatifloxacin Therapy and Dysglycemia in Older Adults". *The New England Journal of Medicine* **354** (13): 1352–1361.

3. Gurwitz, Jerry H. (March 2006). "Serious Adverse Drug Effects — Seeing the Trees through the Forest". *The New England Journal of Medicine* **354** (13): 1413–1415.

4. Lewis-Hall, Freda (February 15, 2006). "Dear Healthcare Provider:" (PDF). Bristol-MyersSquibb.

5. Schmid, Randolph E. (May 1, 2006). "Drug Company Taking Tequin Off Market". Associated Press. <http://www.sfgate.com/cgi-bin/article.cgi?file=/news/archive/2006/05/01/national/w120748D88.DTL&type=health>.

6. Adams M, Tavakoli H (2006). "Gatifloxacin-induced hallucinations in a 19-year-old man". *Psychosomatics* **47** (4): 360.

7. Coleman CI, Spencer JV, Chung JO, Reddy P (2002). "Possible gatifloxacin-induced fulminant hepatic failure". *Ann Pharmacother* **36** (7-8): 1162–7.

8. I Masood, R Bhargava, Z Ahmad, DK Sharma, SZ Rahman, SS Amin. Gatifloxacin-Induced Purpura – An Unusual Adverse Drug Reaction. *J Ind Acad Clinical Med* 2005; **6** (3): 239–240

9. "Two drugs banned". *The Hindu* (Chennai, India). 19 March 2011. <http://www.thehindu.com/news/national/article1551233.ece>.

10. Peggy Peck (2 May 2006). "Bristol-Myers Squibb Hangs No Sale Sign on Tequin". *Med Page Today*. <http://www.medpagetoday.com/PrimaryCare/PreventiveCare/3212>. Retrieved 24 February 2009.

Table 1: Gatifloxacin content of pure and innovator brand of Gatifloxacin tablet as determined by non-aqueous titration using acetus HClO₄ as titrant and crystal violet as indicator

Weight of sample (pure powder / equiv wts of tab.) (g)	Pure Gatifloxacin powder	Powdered Gatifloxacin tab. (Innovator brand)
0.1	99.82 ± 1.48	99.97 ± 2.78
0.2	100.60 ± 1.54	100.01 ± 1.89
0.3	100.58 ± 1.03	100.27 ± 2.05

Table 2: Gatifloxacin content of six brands of Gatifloxacin tablets as determined by non-aqueous titration using acetus HClO₄ as titrant and crystal violet as indicator

S/No.	Product Name and Brand	% Purity
1.	GATTY-400 by Dr. Reddy's	100.60
2.	GATIMAC-400 by Macleod's	100.58
3.	GATIKIND-400 by Mankind	99.97
4.	GATQUIN-400 by Cipla(solan)	100.60
5.	AUSGAT-400 by Austin Pharma	100.01
6.	Q-CAT by Cipla(Mumbai)	100.27